An expert panel of India's drug regulator on Friday sought additional data from drugmaker Dr.Reddy's Laboratories on its Sputnik V COVID-19 vaccine trial, in its second such request after an initial evaluation in February.
The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study, as well as data on serious adverse events and positive cases reported till date.
Dr. Reddy's has been conducting small clinical trials with Sputnik V in India under a deal with Russia's wealth fund. Several Indian companies have signed deals to produce and supply over half a billion doses of the vaccine.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
US Lawmakers Back Covid Chinese Lab Leak Theory After Two-Year Probe New XEC Covid Variant Spreads To 27 Countries, Here's What We Know So Far Study Shows How Long Covid Is Debilitating Children's Health Pics: Rahul Gandhi's Family Lunch At Iconic Delhi Restaurant Is Safe Car Enough? Volvo Crash That Killed CEO, Family Sparks Big Question Can Elon Musk Become US President? Donald Trump Says... 1 Dead As Brazil Bridge Collapses, Truck Carrying Acid Falls Into River Plane Crash Kills Brazil Businessman, 9 Family Members Donald Trump Vows To "Stop Transgender Lunacy" On Day One In Office Track Latest News Live on NDTV.com and get news updates from India and around the world.